Long-term use of hydrocodone vs. oxycodone in primary care.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 09 01 2019
revised: 20 05 2019
accepted: 19 06 2019
pubmed: 11 11 2019
medline: 1 7 2020
entrez: 11 11 2019
Statut: ppublish

Résumé

Hydrocodone and oxycodone are the Schedule II opioids most often prescribed in primary care. Notwithstanding the dangers of prescription opioid use, the likelihood of long-term use with either drug is presently unknown. Using a retrospective cohort design and data from a commerical healthcare claims repository, we compared the likelihood of long-term use of hydrocodone and oxycodone in primary care patients presenting with acute back pain. Treatment was categorized as long-term if the prescription dates spanned ≥90 days from initial prescription to the run-out date of the last prescription, and included ≥120 days' supply or ≥10 fills. Instrumental variable methods and probit regression were used to model the effect of drug choice on long-term use, estimate the average treatment effect, and correct for confounding by indication. A total of 3,983 patients who were prescribed only hydrocodone or only oxycodone were followed for 270 days in 2016. Long-term opioid use was observed in 320 patients (8%). Controlling for potential confounders including morphine milligram equivalents and dosage, an estimated 12% (95 CI, 10%-14%) treated with hydrocodone transitioned to long-term use vs. 2% (95 CI, 1%-3%) on oxycodone. Among patients who received more than one prescription (n = 1,866), an estimated 23% (95 CI, 19%-26%) treated with hydrocodone transitioned to long-term use vs. 5% (95 CI, 3%-7%) on oxycodone. The difference between drugs was supported in sensitivity and subgroup analyses. Sample selection bias was not detected. Long-term use was substantially greater for patients treated with hydrocodone than oxycodone, despite equianalgesia.

Sections du résumé

BACKGROUND
Hydrocodone and oxycodone are the Schedule II opioids most often prescribed in primary care. Notwithstanding the dangers of prescription opioid use, the likelihood of long-term use with either drug is presently unknown.
METHODS
Using a retrospective cohort design and data from a commerical healthcare claims repository, we compared the likelihood of long-term use of hydrocodone and oxycodone in primary care patients presenting with acute back pain. Treatment was categorized as long-term if the prescription dates spanned ≥90 days from initial prescription to the run-out date of the last prescription, and included ≥120 days' supply or ≥10 fills. Instrumental variable methods and probit regression were used to model the effect of drug choice on long-term use, estimate the average treatment effect, and correct for confounding by indication.
RESULTS
A total of 3,983 patients who were prescribed only hydrocodone or only oxycodone were followed for 270 days in 2016. Long-term opioid use was observed in 320 patients (8%). Controlling for potential confounders including morphine milligram equivalents and dosage, an estimated 12% (95 CI, 10%-14%) treated with hydrocodone transitioned to long-term use vs. 2% (95 CI, 1%-3%) on oxycodone. Among patients who received more than one prescription (n = 1,866), an estimated 23% (95 CI, 19%-26%) treated with hydrocodone transitioned to long-term use vs. 5% (95 CI, 3%-7%) on oxycodone. The difference between drugs was supported in sensitivity and subgroup analyses. Sample selection bias was not detected.
CONCLUSIONS
Long-term use was substantially greater for patients treated with hydrocodone than oxycodone, despite equianalgesia.

Identifiants

pubmed: 31707268
pii: S0376-8716(19)30283-2
doi: 10.1016/j.drugalcdep.2019.06.026
pmc: PMC9338763
mid: NIHMS1824370
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Hydrocodone 6YKS4Y3WQ7
Oxycodone CD35PMG570

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

107524

Subventions

Organisme : NIMH NIH HHS
ID : P30 MH097488
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082866
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Gen Hosp Psychiatry. 2009 Nov-Dec;31(6):564-70
pubmed: 19892215
Clin Pharmacol Ther. 2017 Dec;102(6):924-933
pubmed: 28836267
Anesthesiology. 2008 Mar;108(3):495-505
pubmed: 18292687
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Pain Physician. 2009 Jan-Feb;12(1):259-67
pubmed: 19165308
Pain. 2009 Oct;145(3):287-293
pubmed: 19581051
JAMA. 2019 Jun 4;321(21):2059-2062
pubmed: 31034007
Nature. 2018 Jun;558(7711):547-552
pubmed: 29899455
Ann Emerg Med. 2018 Oct;72(4):389-400.e1
pubmed: 30054152
Am J Ind Med. 2009 Feb;52(2):162-71
pubmed: 19016267
Ann Intern Med. 2014 Jul 15;161(2):131-8
pubmed: 25023252
Acad Emerg Med. 2005 Apr;12(4):282-8
pubmed: 15805317
BMJ. 2018 Aug 1;362:k2833
pubmed: 30068513
J Clin Epidemiol. 2011 Jun;64(6):687-700
pubmed: 21163621
Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):627-37
pubmed: 20535759
JAMA Netw Open. 2019 Feb 1;2(2):e187621
pubmed: 30707224
J Gen Intern Med. 2017 Jan;32(1):21-27
pubmed: 27484682
Ann Transl Med. 2018 May;6(10):182
pubmed: 29951504
J Safety Res. 2014 Dec;51:125-9
pubmed: 25453186
Ann Intern Med. 2017 Sep 05;167(5):293-301
pubmed: 28761945
Curr Med Res Opin. 2009 Sep;25(9):2133-50
pubmed: 19601703
JAMA Netw Open. 2019 Mar 1;2(3):e190665
pubmed: 30874783
Clin J Pain. 2010 Jan;26(1):1-8
pubmed: 20026946
Int J Biostat. 2016 May 1;12(1):219-32
pubmed: 27227722
Regul Toxicol Pharmacol. 2011 Apr;59(3):385-90
pubmed: 21215785
Pain. 2015 Apr;156(4):569-576
pubmed: 25785523
Nature. 2012 Mar 21;485(7398):321-6
pubmed: 22437502
Addiction. 2010 Oct;105(10):1776-82
pubmed: 20712819
Pain Med. 2015 Sep 9;17(5):908-914
pubmed: 26349634
Pain Med. 2016 Nov;17(11):2036-2046
pubmed: 27880651
J Pain Symptom Manage. 2009 Sep;38(3):418-25
pubmed: 19735902
Clin J Pain. 2014 Jul;30(7):557-64
pubmed: 24281273
MMWR Morb Mortal Wkly Rep. 2017 Mar 17;66(10):265-269
pubmed: 28301454
Am J Epidemiol. 2015 Feb 1;181(3):191-7
pubmed: 25609096
Pharmacoepidemiol Drug Saf. 2018 May;27(5):495-503
pubmed: 28971545
Am J Public Health. 2018 Sep;108(9):1214-1219
pubmed: 30024809
Stat Med. 2014 Jun 15;33(13):2297-340
pubmed: 24599889
Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):537-54
pubmed: 20354968
Neuron. 2018 Jun 6;98(5):963-976.e5
pubmed: 29754753
Epidemiology. 2013 May;24(3):363-9
pubmed: 23532055
J Pain. 2012 Oct;13(10):988-96
pubmed: 23031398
J Pain Symptom Manage. 2008 Feb;35(2):214-28
pubmed: 18178367
Arch Intern Med. 2010 Dec 13;170(22):1979-86
pubmed: 21149754
Drug Alcohol Depend. 2009 Apr 1;101(1-2):107-14
pubmed: 19118954
Stat Med. 2014 Sep 10;33(20):3528-46
pubmed: 24930696
Epidemiology. 2015 Sep;26(5):690-9
pubmed: 26196683
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49
pubmed: 26987082
J Pain. 2007 Jul;8(7):573-82
pubmed: 17499555
Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):357-367
pubmed: 28239929
Int J Epidemiol. 2018 Oct 1;47(5):1714-1722
pubmed: 29982600
Acta Obstet Gynecol Scand. 2018 Apr;97(4):407-416
pubmed: 29415329
N Engl J Med. 2018 Jul 19;379(3):205-207
pubmed: 29847203
Best Pract Res Clin Rheumatol. 2013 Oct;27(5):663-72
pubmed: 24315147
Curr Epidemiol Rep. 2017;4(4):281-287
pubmed: 29226066
J Am Board Fam Med. 2011 Nov-Dec;24(6):717-27
pubmed: 22086815
Lancet. 2018 Jun 9;391(10137):2368-2383
pubmed: 29573872
Health Serv Res. 2003 Dec;38(6 Pt 1):1385-402
pubmed: 14727779
Pain. 2016 Apr;157(4):849-857
pubmed: 26785321
J Am Acad Orthop Surg. 2019 May 1;27(9):e423-e429
pubmed: 30289795
Pharmacoepidemiol Drug Saf. 2016 May;25(5):560-8
pubmed: 27004714
Neuropsychopharmacology. 2018 Dec;43(13):2514-2520
pubmed: 30250308
Ann Intern Med. 2015 Feb 17;162(4):276-86
pubmed: 25581257
BMJ. 2015 Jan 05;350:g6380
pubmed: 25561513
Nat Commun. 2018 Oct 9;9(1):4022
pubmed: 30301884
Clin J Pain. 2008 Jul-Aug;24(6):521-7
pubmed: 18574361
MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):140-143
pubmed: 30763301

Auteurs

Rebecca Arden Harris (RA)

Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Harris@pennmedicine.upenn.edu.

Henry R Kranzler (HR)

Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; VISN 4 Mental Illness Research, Education and Clinical Center, The Corporal Michael Crescenz VA Medical Center, United States.

Kyong-Mi Chang (KM)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States.

Chyke A Doubeni (CA)

Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Robert Gross (R)

Department of Medicine, Infectious Diseases, Department of Epidemiology, Biostatistics, Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH